L. Vangeel

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir

This paper identifies three substitutions in SARS-CoV-2 3CLpro that confer resistance to nirmatrelvir and other 3CLpro inhibitors in vitro.

A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection

This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.

Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model

This study shows that Ivermectin does not reduce SARS-CoV-2 lung viral load or improve lung pathology in Syrian hamsters and does not enhance Molnupiravir's effect.

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

The paper evaluates the antiviral activity of remdesivir, molnupiravir, and nirmatrelvir against SARS-CoV-2 variants, finding they remain effective.

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents

This study develops a SARS-CoV-2 replication model using primary human airway epithelial cells to test antiviral agents, finding that remdesivir and interferons inhibit replication while AT-511 does not.

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

This study evaluates ALG-097111, a selective SARS-CoV-2 3CLpro inhibitor, showing potent in vitro activity and significant in vivo antiviral effects in Syrian hamsters.

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.